| Name | BAY-299 |
| Description | BAY-299 is an effecitve inhibitor of the bromodomain and PHD finger family member BRPF2 and the TATA box binding protein-associated factors TAF1 and TAF1L with IC50s of 67 nM, 8 nM, and 106 nM, respectively. |
| In vitro | BAY-299 inhibits the cells proliferation of NCI-H526, CHL-1, MOLM-13, MV4-11, 769-P, Jurkat, and 5637 with GI50s of 6860, 7400, 1060, 2630, 3210, 3900, and 7980 nM, respectively. BAY-299 blocks the interaction of BRPF2 BD with H4 and H3.3 with IC50s of 575 and 825 nM, respectively[1]. |
| In vivo | The in vivo pharmacokinetic properties of BAY-299 in rats show are blood clearance is low (17% of hepatic blood flow), terminal half-life long to very long with t1/2 of 10 h, volume of distribution in steady-state high, and bioavailability high with F of 73%[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 20 mg/mL (46.6 mM), Sonication and heating are recommended.
|
| Keywords | BAY-299 |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin | GSK1379725A |
| Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Bioactive Compounds Library Max |
United States
